V K Kimiskidis1, E Papadakis2, V Papaliagkas1, S Papagiannopoulos3, D K Galanakis4. 1. Laboratory of Clinical Neurophysiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 2. Hematology Dept-Hemostasis Unit, Papageorgiou General Hospital, Thessaloniki, Greece. 3. 3 Department of Neurology, G.Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Pathology Department of Stony Brook University, Stony Brook, New York.
Abstract
BACKGROUND: The inherited dysfibrinogenemias comprise rare congenital coagulation disorders which are clinically characterized by bleeding diathesis and, in occasional patients, by thrombotic tendency or combined bleeding-thrombotic events. In recent years, accumulating evidence suggested that fibrinogen has a critical role in the pathogenesis of neuroinflammatory disorders, including multiple sclerosis. We describe the presentation and long-term follow-up of a patient with inherited dysfibrinogenemia and concomitant clinical and laboratory evidence of demyelinating disease. Case description: A 16-year-old male patient presented in 2003 with bilateral sensory symptomatology preceded by an episode of epistaxis. His past medical history included episodes of spontaneous nosebleeds as well as Duane syndrome and mild atrophy of the right upper limb. Coagulation testing of the patient and his asymptomatic father revealed in both the presence of a clotting defect, consistent with inherited dysfibrinogenemia (named Fibrinogen Thessaloniki). Within seven months, the patient presented with a new episode of motor semiology whereas serial brain magnetic resonance imaging (MRI) scans revealed T2 lesions with bilateral distribution, some of which with gadolinium enhancement. The cerebrospinal fluid examination disclosed the presence of oligoclonal bands in the central nervous system compartment. The patient was started on azathioprine (2.5 mg/kg/24h) which led to clinical and radiological stabilization for nine years. In 2013, the dose of azathioprine was reduced, due to an elevation of his amylase levels, resulting in radiological deterioration with an increased T2 lesion load. The reinstitution of azathioprine at therapeutic doses led to radiological improvement and clinical stability as of today. CONCLUSION: The described case of inherited dysfibrinogenemia and concomitant multiple sclerosis provides speculative evidence for a causal link, rather than a chance association, between these two entities. Further studies are warranted to corroborate this hypothesis in experimental and clinical settings. HIPPOKRATIA 2017, 21(1): 49-51.
BACKGROUND: The inherited dysfibrinogenemias comprise rare congenital coagulation disorders which are clinically characterized by bleeding diathesis and, in occasional patients, by thrombotic tendency or combined bleeding-thrombotic events. In recent years, accumulating evidence suggested that fibrinogen has a critical role in the pathogenesis of neuroinflammatory disorders, including multiple sclerosis. We describe the presentation and long-term follow-up of a patient with inherited dysfibrinogenemia and concomitant clinical and laboratory evidence of demyelinating disease. Case description: A 16-year-old male patient presented in 2003 with bilateral sensory symptomatology preceded by an episode of epistaxis. His past medical history included episodes of spontaneous nosebleeds as well as Duane syndrome and mild atrophy of the right upper limb. Coagulation testing of the patient and his asymptomatic father revealed in both the presence of a clotting defect, consistent with inherited dysfibrinogenemia (named Fibrinogen Thessaloniki). Within seven months, the patient presented with a new episode of motor semiology whereas serial brain magnetic resonance imaging (MRI) scans revealed T2 lesions with bilateral distribution, some of which with gadolinium enhancement. The cerebrospinal fluid examination disclosed the presence of oligoclonal bands in the central nervous system compartment. The patient was started on azathioprine (2.5 mg/kg/24h) which led to clinical and radiological stabilization for nine years. In 2013, the dose of azathioprine was reduced, due to an elevation of his amylase levels, resulting in radiological deterioration with an increased T2 lesion load. The reinstitution of azathioprine at therapeutic doses led to radiological improvement and clinical stability as of today. CONCLUSION: The described case of inherited dysfibrinogenemia and concomitant multiple sclerosis provides speculative evidence for a causal link, rather than a chance association, between these two entities. Further studies are warranted to corroborate this hypothesis in experimental and clinical settings. HIPPOKRATIA 2017, 21(1): 49-51.
Authors: Ah-Ling Cheng; Saima Batool; Cheryl R McCreary; M L Lauzon; Richard Frayne; Mayank Goyal; Eric E Smith Journal: Stroke Date: 2013-08-06 Impact factor: 7.914
Authors: Jae Kyu Ryu; Mark A Petersen; Sara G Murray; Kim M Baeten; Anke Meyer-Franke; Justin P Chan; Eirini Vagena; Catherine Bedard; Michael R Machado; Pamela E Rios Coronado; Thomas Prod'homme; Israel F Charo; Hans Lassmann; Jay L Degen; Scott S Zamvil; Katerina Akassoglou Journal: Nat Commun Date: 2015-09-10 Impact factor: 14.919
Authors: Dimitrios Davalos; Jae Kyu Ryu; Mario Merlini; Kim M Baeten; Natacha Le Moan; Mark A Petersen; Thomas J Deerinck; Dimitri S Smirnoff; Catherine Bedard; Hiroyuki Hakozaki; Sara Gonias Murray; Jennie B Ling; Hans Lassmann; Jay L Degen; Mark H Ellisman; Katerina Akassoglou Journal: Nat Commun Date: 2012 Impact factor: 14.919